Alfieri Michael 4

What Happened
Michael Alfieri, Principal Financial Officer of Aldeyra Therapeutics (ALDX), reported a purchase of 5,000 common shares on 2026-03-18. The shares were acquired at $1.42 per share for a total reported value of $7,100. The transaction is recorded as a purchase (code P), which is an insider buy rather than a sale.

Key Details

• Transaction date: 2026-03-18; reported on Form 4 filed 2026-03-19.
• Price and size: 5,000 shares at $1.42 each; total = $7,100.
• Transaction code: P (purchase — open market or private purchase as reported). The filing does not specify whether this was an open-market trade or a private placement.
• Shares owned after transaction: Not specified in the information provided on this filing.
• Footnotes/plan: No 10b5-1 plan, tax-withholding, or other footnotes reported in the summary provided.
• Timeliness: Filed the day after the transaction (appears timely under Form 4 rules).

Context
Insider purchases are often watched by investors as a potential positive signal, but a small purchase (here, $7.1k) can be routine and doesn’t by itself indicate material insider conviction. This report documents a straightforward purchase by Aldeyra’s principal financial officer; no additional context (e.g., large stakes, 10% ownership, or derivative exercises) was reported.